CORDIS
EU research results

CORDIS

English EN
Fate and effects of cytostatic pharmaceuticals in the environment and the identification of biomarkers for and improved risk assessment on environmental exposure

Fate and effects of cytostatic pharmaceuticals in the environment and the identification of biomarkers for and improved risk assessment on environmental exposure

Objective

CytoThreat addresses the need to assess the risks of pharmaceuticals released in the environment, focusing on cytostatic drugs because they are highly hazardous compounds due to their genotoxic properties which may cause unexpected long term effects. Their release in the environment may lead to systemic ecological effects and increased cancer incidence, reduced fertility and malformations in the offspring in humans. The occurrence, distribution and fate of selected widely used cytostatics in different aquatic matrices, their acute and chronic toxicity and impact on the stability of the genetic material in a variety of aquatic organisms representing different trophic levels is addressed to provide data sets necessary for scientifically based risk assessment. Special emphasis is put on the combined effects of environmentally relevant mixtures. A combination of state-of-the art analytical chemistry, in vivo and in vitro systems, and ‘OMICS’ technologies is applied. In vivo studies with zebrafish models aim at identifying linkages between the genomic profiles, exposure conditions and adverse effects in vertebrates to identify molecular biomarkers for adverse effects of specific groups of cytostatics to be used as diagnostic markers and for predicting synergistic effects of combined exposures. Comparative in vitro genotoxicity and transcriptomic studies with zebrafish and human derived cells will provide additional information for the extrapolation of toxicological data to humans. Comparisons with the hazardous effects of other groups of pharmaceuticals will provide knowledge on the magnitude of the problem. CytoThreat will generate new knowledge on environmental and health risks of cytostatics and provide objective arguments for recommendations and regulations. Partners form 5 member states and 2 associated countries with complementary expertise in analytical chemistry, aquatic and genetic toxicology, and genomics and bioinformatics are involved.

Coordinator

NACIONALNI INSTITUT ZA BIOLOGIJO

Address

Vecna Pot 111
1000 Ljubljana

Slovenia

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 609 334,65

Administrative Contact

Potocnik Franc (Mr.)

Participants (8)

Sort alphabetically

Sort by EU Contribution

Expand all

INSTITUT JOZEF STEFAN

Slovenia

EU Contribution

€ 407 730

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 292 867,20

SZENT ISTVAN UNIVERSITY

Hungary

EU Contribution

€ 224 334,40

UNIVERSITA DEGLI STUDI DELLA CAMPANIA LUIGI VANVITELLI

Italy

EU Contribution

€ 288 563,20

AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS

Spain

EU Contribution

€ 419 018,25

Institut za medicinska istrazivanja i medicinu rada

Croatia

EU Contribution

€ 114 122,80

INSTITUT ZA MULTIDISCIPLINARNA ISTRAZIVANJA

Serbia

EU Contribution

€ 69 243,20

RR & CO. RAZISKAVE RAZVOJ IN PRENOS ZNANJA DOO

Slovenia

EU Contribution

€ 157 745,60

Project information

Grant agreement ID: 265264

Status

Closed project

  • Start date

    1 January 2011

  • End date

    31 December 2014

Funded under:

FP7-ENVIRONMENT

  • Overall budget:

    € 3 293 999,80

  • EU contribution

    € 2 582 959,30

Coordinated by:

NACIONALNI INSTITUT ZA BIOLOGIJO

Slovenia